The study team observed that the athlete resumed structured treadmill activity on Day +1 after matched-sibling peripheral blood stem cell transplantation. Cytopenias were profound during the first month: a WBC nadir of 0.04 ×10^9/L (Day +9), platelets 11 ×10^9/L (Day +9), and hemoglobin down to 8.3 g/dL (Day +11). Despite these laboratory values, the participant performed near-daily treadmill walking sessions of at least 30 minutes at 6.0–6.4 km/h with 2%–7% incline, targeting approximately 60% heart-rate reserve and recording RPEs of 4–6. Exercise was limited to low-impact treadmill walking during the platelet nadir, and sessions were omitted or intensity reduced when gastrointestinal symptoms or other issues occurred. Investigators reported no episodes of exaggerated tachycardia or orthostatic instability during this phase.
Body mass declined from 71.7 kg before conditioning to 66.4 kg on Day +24 and rebounded to roughly baseline by Day +92. A short readmission for a culture-negative febrile episode occurred on Day +27; no infectious source was identified and intravenous immunoglobulin was started for transplant-associated hypogammaglobulinemia. A chemotherapy-associated sensory peripheral neuropathy persisted during early recovery and was documented in training logs.
Independent laboratories performed three CPETs: one 5 months pre-HCT and two post-HCT (7 and 20 months). The pre-HCT and 7-month assessments were maximal graded tests using a constant-speed protocol at 16.1 km/h with 1-minute stage increases in gradient; the 20-month assessment was intentionally submaximal and terminated at an RPE of 7.5/10. Because the original reports came from different laboratories and numerical breath-by-breath data were not available for all tests, the authors applied consistent physiological criteria where possible but acknowledged heterogeneity in available records.
Directly measured VO2 peak was reported as 75.8 mL/kg/min pre-HCT and 71.5 mL/kg/min at 7 months post-HCT. The 20-month CPET was submaximal; therefore a post-HCT VO2 peak was not determined at that timepoint. VT1 was identified across all three assessments: approximately 53.0 mL/kg/min pre-HCT, 48.0 at 7 months, and 42.4 at 20 months. VT2 was identified on the pre-HCT and 7-month tests at about 66.0 and 59.9 mL/kg/min, respectively; VT2 could not be determined with confidence at 20 months because gas-exchange responses did not corroborate a discrete respiratory compensation point. The authors noted that some threshold values for the pre-HCT test were estimated from graphical outputs due to absent numerical data.
The participant maintained prospective training logs that recorded treadmill workload, heart rate, and perceived exertion. These contemporaneous records were cross-checked against transplant-center documentation and found to agree. Incremental progression is documented: incline interval progression during Days +15 to +89 at 60–70% HRR; first sustained run of 3 miles on Day +87; and multiple 5K performances in the early post-engraftment period.
Significant race-level results occurred during a later phase of immune complication management. While receiving prednisone plus cyclosporine for active cGvHD, the athlete recorded a 5K of 17:55 (Day +314) and a 10K of 41:00 (Day +340). These performances were recorded in the training log alongside heart-rate data (peak heart rates 166 and 157 bpm for those events, respectively) and RPEs indicating high effort. The report documents that structured training continued through corticosteroid-treated cGvHD, with alternating prednisone dosing during an 18–22 month window described in the timeline.
The transplant indication was diffuse large B-cell lymphoma arising from transformation of follicular lymphoma. The participant underwent reduced-intensity conditioning with alemtuzumab, fludarabine, and melphalan, then received matched sibling peripheral blood stem cells. Baseline cardiopulmonary measures before conditioning included a left ventricular ejection fraction of 68% and FEV1 of 98% predicted. GvHD prophylaxis included in vivo T-cell depletion with alemtuzumab in conditioning and cyclosporine. Donor lymphocyte infusions and the evolution of donor chimerism are referenced in the case timeline; the report aligned daily training data to these immunologic events but did not provide detailed numeric chimerism timelines within the available text.
Authors emphasized methodological heterogeneity: CPETs were independently obtained at different laboratories with incomplete breath-by-breath data, inconsistent documentation of calibration and termination criteria, and graphical estimation used where numerical data were missing. The single-patient design precludes generalization. The source did not report standardized, protocol-driven exercise prescriptions or prospective safety monitoring as part of a trial; training was patient-directed and logged prospectively by the participant. The report therefore cannot establish safety thresholds, dosing recommendations, or efficacy for structured high-intensity training after allogeneic HCT. Future work should prospectively test reproducible CPET protocols, define objective safety criteria during profound cytopenia, and examine whether these observations are reproducible across broader HCT populations.